AV-101

Why 93% Of Aerovate Therapeutics' Value Just Went Up In Smoke
Investors Business Daily
Tue, 06/18/24 - 11:29 am
Aerovate Therapeutics
hypertension
clinical trials
AV-101
VistaGen fails phase 2 depression trial, sparking stock rout
Fierce Biotech
Thu, 11/14/19 - 10:36 am
VistaGen
AV-101
major depressive disorder
clinical trials
VistaGen’s AV-101 Snags Fast Track Designation, Other Drugmakers Move Ahead with Non-Opioid Pain Treatment Programs
BioSpace
Mon, 10/8/18 - 09:53 am
VistaGen
AV-101
FDA
fast track
neuropathic pain
BioWave
Virpax Pharmaceuticals